SkinHealth Systems Statistics
Total Valuation
SKIN has a market cap or net worth of $106.71 million. The enterprise value is $259.56 million.
| Market Cap | 106.71M |
| Enterprise Value | 259.56M |
Important Dates
The last earnings date was Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SKIN has 6.54 million shares outstanding. The number of shares has increased by 2.50% in one year.
| Current Share Class | 6.54M |
| Shares Outstanding | 6.54M |
| Shares Change (YoY) | +2.50% |
| Shares Change (QoQ) | +0.47% |
| Owned by Insiders (%) | 9.01% |
| Owned by Institutions (%) | 24.53% |
| Float | 3.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 7.38 |
| PS Ratio | 0.37 |
| Forward PS | 0.37 |
| PB Ratio | 1.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 4.70 |
| P/OCF Ratio | 4.53 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.22, with an EV/FCF ratio of 11.44.
| EV / Earnings | n/a |
| EV / Sales | 0.90 |
| EV / EBITDA | 9.22 |
| EV / EBIT | 37.56 |
| EV / FCF | 11.44 |
Financial Position
The company has a current ratio of 2.89, with a Debt / Equity ratio of 4.74.
| Current Ratio | 2.89 |
| Quick Ratio | 1.89 |
| Debt / Equity | 4.74 |
| Debt / EBITDA | 7.97 |
| Debt / FCF | 11.64 |
| Interest Coverage | 0.27 |
Financial Efficiency
Return on equity (ROE) is -30.13% and return on invested capital (ROIC) is 3.24%.
| Return on Equity (ROE) | -30.13% |
| Return on Assets (ROA) | 0.97% |
| Return on Invested Capital (ROIC) | 3.24% |
| Return on Capital Employed (ROCE) | 2.16% |
| Weighted Average Cost of Capital (WACC) | 8.28% |
| Revenue Per Employee | $470,737 |
| Profits Per Employee | -$29,838 |
| Employee Count | 613 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.85 |
Taxes
In the past 12 months, SKIN has paid $5.10 million in taxes.
| Income Tax | 5.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.68% in the last 52 weeks. The beta is 1.06, so SKIN's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | -38.68% |
| 50-Day Moving Average | 12.55 |
| 200-Day Moving Average | 15.89 |
| Relative Strength Index (RSI) | 67.13 |
| Average Volume (20 Days) | 75,214 |
Short Selling Information
The latest short interest is 358,652, so 5.48% of the outstanding shares have been sold short.
| Short Interest | 358,652 |
| Short Previous Month | 375,655 |
| Short % of Shares Out | 5.48% |
| Short % of Float | 11.31% |
| Short Ratio (days to cover) | 9.09 |
Income Statement
In the last 12 months, SKIN had revenue of $288.56 million and -$18.29 million in losses. Loss per share was -$2.84.
| Revenue | 288.56M |
| Gross Profit | 193.96M |
| Operating Income | 6.91M |
| Pretax Income | -13.19M |
| Net Income | -18.29M |
| EBITDA | 28.14M |
| EBIT | 6.91M |
| Loss Per Share | -$2.84 |
Balance Sheet
The company has $111.39 million in cash and $264.24 million in debt, with a net cash position of -$152.85 million or -$23.36 per share.
| Cash & Cash Equivalents | 111.39M |
| Total Debt | 264.24M |
| Net Cash | -152.85M |
| Net Cash Per Share | -$23.36 |
| Equity (Book Value) | 55.76M |
| Book Value Per Share | 8.56 |
| Working Capital | 131.75M |
Cash Flow
In the last 12 months, operating cash flow was $23.58 million and capital expenditures -$883,000, giving a free cash flow of $22.69 million.
| Operating Cash Flow | 23.58M |
| Capital Expenditures | -883,000 |
| Depreciation & Amortization | 21.23M |
| Net Borrowing | -123.48M |
| Free Cash Flow | 22.69M |
| FCF Per Share | $3.47 |
Margins
Gross margin is 67.22%, with operating and profit margins of 2.39% and -6.34%.
| Gross Margin | 67.22% |
| Operating Margin | 2.39% |
| Pretax Margin | -4.57% |
| Profit Margin | -6.34% |
| EBITDA Margin | 9.75% |
| EBIT Margin | 2.39% |
| FCF Margin | 7.86% |
Dividends & Yields
SKIN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.50% |
| Shareholder Yield | -2.50% |
| Earnings Yield | -17.42% |
| FCF Yield | 21.27% |
Analyst Forecast
The average price target for SKIN is $14.50, which is -11.10% lower than the current price. The consensus rating is "Hold".
| Price Target | $14.50 |
| Price Target Difference | -11.10% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 0.16% |
| EPS Growth Forecast (3Y) | -10.86% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on October 14, 2026. It was a reverse split with a ratio of 1:20.
| Last Split Date | Oct 14, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
SKIN has an Altman Z-Score of -0.45 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.45 |
| Piotroski F-Score | 5 |